FGFR2 and hyperphosphatemia: In pre-clinical studies, lirafugratinib inhibited FGFR2 phosphorylation, downstream signalling and proliferation of FGFR2-amplified SNU-16 GC cells in vitro and in vivo, and notably induced significantly less hyperphosphatemia compared to pan-FGFR inhibitors [90].